Concentric Analgesics
Latest round
- Series B
Last raised
- May 2019
Total raised
- $77M
Investors
- 4
About Concentric Analgesics
Concentric Analgesics, Inc.Concentric Analgesics, Inc. specializes in developing novel therapeutics for pain management. Founded in 2014 and headquartered in San Francisco, US, the company has engaged in three deals, with the most recent completed on January 26, 2022. The company's founder, Craig Husfeld, has a history of involvement in related ventures.Concentric Analgesics, Inc. specializes in developing a portfolio of novel, non-opioid therapeutics tailored for long-lasting pain relief following a single local administration. The company's main product offerings are based on a unique class of TRPV1 agonist prodrugs aimed at addressing the pervasive issues associated with pain management, particularly in the context of cancer treatment and osteoarthritis. These products are designed to target pain at its source while minimizing systemic exposure, thereby reducing the risk of opioid-related adverse events. The intended end users encompass patients experiencing moderate to severe pain, particularly those recovering from surgery or managing chronic conditions.Revenue generation for Concentric Analgesics is centered around the commercialization of its innovative pain relief products. The company engages in business-to-business (B2B) transactions with healthcare providers, hospitals, and clinics, facilitating access to their therapeutics for patient treatment. The transaction structure typically involves direct sales to these institutions, which may include bulk purchasing agreements and contracts for supply. These arrangements enable healthcare facilities to incorporate Concentric’s products into their pain management protocols.In January 2022, Concentric Analgesics, Inc. The company aims to further enhance its product lineup and expand its presence in international markets, particularly targeting Europe and Asia by 2023.
Who invested in Concentric Analgesics
4 investors across 1 round
See all investors in Concentric Analgesics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
May 13, 2019
Amount
$77M
Investors
Questions about Concentric Analgesics
Who invested in Concentric Analgesics?
Concentric Analgesics has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Concentric Analgesics raised?
Concentric Analgesics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Concentric Analgesics last raise money?
Concentric Analgesics's most recent round on record is a Series B, in May 2019.
What does Concentric Analgesics do?
Concentric Analgesics is a biotechnology company.
Where is Concentric Analgesics headquartered?
Concentric Analgesics is headquartered in San Francisco, US.
Which VCs invest in companies like Concentric Analgesics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Concentric Analgesics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Concentric Analgesics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.